If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

YieldMax MRNA Option Income Strategy ETF's distributions have increased alongside MRNA's share price resurgence. See more on MRNY ETF here.

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer ...

With $30 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI), Merck & Co. | The project, which involves Merck, SK Biosciences, Hilleman Laboratories and CDMO IDT ...

CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S.

Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine - which designs nanotechnology-based platforms for clinical translation across specialties - developed a ...

Driven by rapid growth in e-grocery, pharmaceutical cold chains, and energy-efficient retail cooling, the global commercial ...

Here are some of the stories Wall Street is watching on Thursday, Jan 22. All three of the major indexes are rising as President Trump cools his rhetoric on Greenland. Mortgage rates ticked higher, ...